Original Article
Severe and uncontrolled asthma in China: a cross-sectional survey from the Australasian Severe Asthma Network Gang Wang1, Fang Wang2, Peter G. Gibson3,4,5, Michael Guo4, Wei-Jie Zhang6, Peng Gao7, Hong-Ping Zhang1, Erin S. Harvey5, Hui Li6, Jie Zhang7 1
Pneumology Group, Department of Integrated Traditional Chinese and Western Medicine, State Key Laboratory of Biotherapy, West China
Hospital, Sichuan University, and Collaborative Innovation Centre for Biotherapy, Chengdu 610041, China; 2Norman Bethune College of Medicine, Jilin University, Changchun 130021, China; 3Department of Respiratory and Sleep Medicine, John Hunter Hospital, Hunter Medical Research Institute, University of Newcastle, Priority Research Centre for Healthy Lungs, New Lambton Heights, NSW, Australia; 4Australasian Severe Asthma Network, Clinical Management, Woolcock Institute of Medical Research, University of Sydney, Glebe, NSW, Australia; 5Australasian Severe Asthma Network, School of Medicine and Public Health, Faculty of Health and Medicine, University of Newcastle; Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute, New Lambton Heights, NSW, Australia; 6Department of Respiratory and Critical Care Medicine, The People’s Hospital of Jilin Province, Changchun, Jilin 130000, China; 7Department of Respiratory and Critical Care Medicine, The 2nd Affiliated Hospital, Jilin University, Changchun, Jilin 130041, China Contributions: (I) Conception and design: PG Gibson; (II) Administrative support: PG Gibson, G Wang, F Wang, M Guo, ES Harvey, J Zhang; (III) Provision of study materials or patients: PG Gibson, G Wang, F Wang, J Zhang; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: PG Gibson, G Wang, F Wang, WJ Zhang, P Gao, HP Zhang, H Li, J Zhang; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Prof. Peter G. Gibson. Level 2, West Wing, Hunter Medical Research Institute, John Hunter Hospital, Locked Bag 1 Hunter Region Mail Centre, NSW 2310, Australia. Email: [email protected]; Prof. Jie Zhang. Department of Respiratory and Critical Care Medicine, The 2nd Affiliated Hospital, Jilin University, Changchun, Jilin 130041, China. Email: [email protected].
Background: Severe asthma is largely unexplored in the Chinese population. Patients with asthma underwent systematic evaluation, by investigating the characteristics of uncontrolled asthma and of asthma treated with three different controller therapies. Methods: This multi-centre, real-world study was conducted from March 2014 to September 2015. Adults with stable asthma underwent assessment of medication use, asthma control, quality of life, psychological symptoms, work productivity and activity impairment, bronchodilator response and sputum induction. Results: Participants (n=379) had a mean (SD) age of 47.4 (14.0) years, and 57.0% were female. There were 14.8% (n=56) of patients receiving treatment with Step 4/5 as severe asthma, but only 13 (3.4%) met ERS/ATS severe refractory asthma criteria. The patients with severe asthma usually used triple controller therapy: ICS/LABA, additional leukotriene modifier or theophylline, and reported better asthma control. Two fifths of patients (n=147) had uncontrolled asthma, with worse symptoms, psychological symptoms (both P
Severe and uncontrolled asthma in China: a cross-sectional survey from the Australasian Severe Asthma Network Gang Wang1, Fang Wang2, Peter G. Gibson3,4,5, Michael Guo4, Wei-Jie Zhang6, Peng Gao7, Hong-Ping Zhang1, Erin S. Harvey5, Hui Li6, Jie Zhang7 1
Pneumology Group, Department of Integrated Traditional Chinese and Western Medicine, State Key Laboratory of Biotherapy, West China
Hospital, Sichuan University, and Collaborative Innovation Centre for Biotherapy, Chengdu 610041, China; 2Norman Bethune College of Medicine, Jilin University, Changchun 130021, China; 3Department of Respiratory and Sleep Medicine, John Hunter Hospital, Hunter Medical Research Institute, University of Newcastle, Priority Research Centre for Healthy Lungs, New Lambton Heights, NSW, Australia; 4Australasian Severe Asthma Network, Clinical Management, Woolcock Institute of Medical Research, University of Sydney, Glebe, NSW, Australia; 5Australasian Severe Asthma Network, School of Medicine and Public Health, Faculty of Health and Medicine, University of Newcastle; Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute, New Lambton Heights, NSW, Australia; 6Department of Respiratory and Critical Care Medicine, The People’s Hospital of Jilin Province, Changchun, Jilin 130000, China; 7Department of Respiratory and Critical Care Medicine, The 2nd Affiliated Hospital, Jilin University, Changchun, Jilin 130041, China Contributions: (I) Conception and design: PG Gibson; (II) Administrative support: PG Gibson, G Wang, F Wang, M Guo, ES Harvey, J Zhang; (III) Provision of study materials or patients: PG Gibson, G Wang, F Wang, J Zhang; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: PG Gibson, G Wang, F Wang, WJ Zhang, P Gao, HP Zhang, H Li, J Zhang; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Prof. Peter G. Gibson. Level 2, West Wing, Hunter Medical Research Institute, John Hunter Hospital, Locked Bag 1 Hunter Region Mail Centre, NSW 2310, Australia. Email: [email protected]; Prof. Jie Zhang. Department of Respiratory and Critical Care Medicine, The 2nd Affiliated Hospital, Jilin University, Changchun, Jilin 130041, China. Email: [email protected].
Background: Severe asthma is largely unexplored in the Chinese population. Patients with asthma underwent systematic evaluation, by investigating the characteristics of uncontrolled asthma and of asthma treated with three different controller therapies. Methods: This multi-centre, real-world study was conducted from March 2014 to September 2015. Adults with stable asthma underwent assessment of medication use, asthma control, quality of life, psychological symptoms, work productivity and activity impairment, bronchodilator response and sputum induction. Results: Participants (n=379) had a mean (SD) age of 47.4 (14.0) years, and 57.0% were female. There were 14.8% (n=56) of patients receiving treatment with Step 4/5 as severe asthma, but only 13 (3.4%) met ERS/ATS severe refractory asthma criteria. The patients with severe asthma usually used triple controller therapy: ICS/LABA, additional leukotriene modifier or theophylline, and reported better asthma control. Two fifths of patients (n=147) had uncontrolled asthma, with worse symptoms, psychological symptoms (both P
